Investors

Investors

Corporate Profile

We are a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases.

Leveraging our proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, we have developed a pipeline of product candidates targeting markets with high unmet medical needs. Our initial focus is on the treatment of blood cancers, including acute lymphoblastic leukemia, or ALL, and acute myeloid leukemia, or AML, by depriving tumors of nutrients necessary for their survival, which is referred to as tumor starvation.

Stock Quote

Exchange
Price
Change (%)
Volume
Data as of
Exchange
Price
Change (%)
Volume
Data as of
More >>

Recent News

Date Title and Summary Additional Formats
Toggle Summary Monthly information related to total number of voting rights and shares composing the share capital – September 30, 2019
Article 223-16 of general regulation of French Autorité des Marchés Financiers   LYON, France , Oct. 04, 2019 (GLOBE NEWSWIRE) -- Listing markets: Euronext Paris from Euronext (Market segment C -  ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States (Symbol :
View HTML
Toggle Summary ERYTECH Provides Business Update and Reports Financial Results for the First Half of 2019
Conference call and webcast on Wednesday, September 18 at 2:30 pm CET / 8:30 am EDT TRYbeCA1, Phase 3 trial for eryaspase in second line pancreatic cancer, progressing on plan Immune modulation collaboration entered into with SQZ Biotechnologies Board strengthened with appointment of Dr.
View HTML
Toggle Summary ERYTECH to Host Second Quarter 2019 Conference Call and Business Update
LYON, France , Sept. 11, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host its second
View HTML
Toggle Summary Monthly information related to total number of voting rights and shares composing the share capital – August 31, 2019
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France , Sept. 03, 2019 (GLOBE NEWSWIRE) -- Listing markets: Euronext Paris from Euronext (Market segment C -  ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States (Symbol :
View HTML
More >>

Upcoming Events

Date Event Details
Summary Toggle Nov 7, 2019

Business Update and Financial Highlights for the 3rd quarter of 2019

Summary Toggle Nov 8, 2019 at 8:30 AM EST

Erytech Pharma Third Quarter 2019 Conference Call and Webcast

Summary Toggle Nov 20 - Nov 21, 2019

Jefferies Health Care Conference, London

RECEIVE E-MAIL ALERTS

Copyright West LLC. Minimum 15 minutes delayed.

Top